Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

导出 OA

翻译打印收藏纠错

第一作者： Adam D,Cohen

第一单位： Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

作者： Adam D,Cohen ^[1] ; María-Victoria,Mateos ^[2] ; Yael C,Cohen ^[3] ; Paula,Rodriguez-Otero ^[4] ; Bruno,Paiva ^[4] ; Niels W C J,van de Donk ^[5] ; Thomas,Martin ^[6] ; Attaya,Suvannasankha ^[7] ; Kevin C,De Braganca ^[8] ; Christina,Corsale ^[8] ; Jordan M,Schecter ^[8] ; Helen,Varsos ^[8] ; William,Deraedt ^[9] ; Liwei,Wang ^[8] ; Martin,Vogel ^[10] ; Tito,Roccia ^[10] ; Xiaoying,Xu ^[8] ; Pankaj,Mistry ^[11] ; Enrique,Zudaire ^[12] ; Muhammad,Akram ^[13] ; Tonia,Nesheiwat ^[13] ; Lida,Pacaud ^[13] ; Irit,Avivi ^[3] ; Jesus,San-Miguel ^[4]

作者单位： Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. ^[1] Hospital Clinico Universitario de Salamanca, Salamanca, Spain. ^[2] Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[3] Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain. ^[4] Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands. ^[5] UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. ^[6] Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN. ^[7] Janssen R&D, Raritan, NJ. ^[8] Janssen R&D, Beerse, Belgium. ^[9] Janssen Global Services, LLC, Raritan, NJ. ^[10] Janssen R&D, High Wycombe, United Kingdom. ^[11] Janssen R&D, Springhouse, PA. ^[12] Legend Biotech USA Inc., Piscataway, NJ. ^[13]